ArticlePloS one2017
Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Autoimmune hepatitis in children: Guidelines of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN).Hepatology international · 2025Guideline
- KASL clinical practice guidelines for management of autoimmune hepatitis 2022.Clinical and molecular hepatology · 2023Guideline
- Clinical Outcomes of Children With Autoimmune Hepatitis in Korea: A Nationwide Multicenter Study.Journal of Korean medical science · 2026Article
- The Geoepidemiology of Autoimmune Hepatitis.Clinical reviews in allergy & immunology · 2026Review
- Incidence and risk factors of hepatocellular carcinoma in patients with autoimmune hepatitis in Asia.JHEP reports : innovation in hepatology · 2025Article
- Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead.Immunologic research · 2025Review
- Article
- Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025Review
- A Preliminary Study on Clinical Characteristics of Patients With Autoimmune Liver Following Coronavirus Disease 2019.Journal of tropical medicine · 2025Article
- Clinical characteristics and outcomes in 50 children with autoimmune hepatitis: a retrospective study from a single centre in China.Frontiers in medicine · 2025Article
- Advances in the Treatment of Autoimmune Hepatitis.Journal of clinical and translational hepatology · 2024Review
- Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database.Orphanet journal of rare diseases · 2024Article
- Denosumab-induced autoimmune hepatitis: Case report.Clinical case reports · 2024Article
- Global incidence and prevalence of autoimmune hepatitis, 1970-2022: a systematic review and meta-analysis.EClinicalMedicine · 2023Article
- Autoimmune hepatitis and overlap syndrome among Alaska Native people: Prevalence, clinical characteristics, and remission.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- [Treatment of Autoimmune Hepatitis].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- [Epidemiology of Autoimmune Liver Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- Epidemiology and updated management for autoimmune liver disease.Clinical and molecular hepatology · 2023Article
- Population-based study for the comorbidities and associated factors in Ménière's disease.Scientific reports · 2022Article
- The Gut Microbiota: A Novel Player in Autoimmune Hepatitis.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimLittle is known about population-based epidemiology and disease burden of autoimmune hepatitis (AIH). The aim of this study was to investigate the prevalence, incidence, comorbidity and direct medical cost of AIH in South Korea.
methodsThe data was from the nationwide, population-based National Health Insurance Service claims database and the Rare Intractable Disease registration program. Age and gender-specific prevalence rates were calculated, and data on comorbidity, diagnostic tests, prescribed drugs, and medical costs were retrieved for patients registered under the disease code K75.4 (AIH) from 2009 to 2013.
resultsA total of 4,085 patients with AIH were identified between 2009 and 2013 with a female-to-male ratio of 6.4. The age-adjusted prevalence rate was 4.82/100,000 persons and gender adjusted prevalence rates were 8.35 in females and 1.30 in males. The age-adjusted calculated incidence rate was 1.07/100,000 persons (gender-adjusted 1.83 in females and 0.31 in males). Ascites, variceal bleeding, and hepatocellular carcinoma were found in 1.4%, 1.3%, and 2.2% of the patients, respectively. Forty-six patients (1.1%) underwent liver transplantation during the study period. Case-fatality was 2.18%. Corticosteroid and azathioprine were prescribed in 44.1% and 38.0% of prevalent patients with AIH in 2013, respectively. The nationwide total direct medical cost was less than 4.0 million USD, and the average cost for each patient was 1,174 USD in 2013.
conclusionThis is the first report on the nationwide epidemiology of AIH in Korea, and it showed a lower prevalence than that of Western countries with considerable disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.